Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

ProQR Therapeutics

NASDAQ PRQR
$1.91 -0.08 -3.93%
Today share price
Netherlands
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 19 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

155.80M
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
42.68M
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
0.43
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
81.57M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-3.54 %

Upcoming events ProQR Therapeutics

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart ProQR Therapeutics

Stock analysis ProQR Therapeutics

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-5.82 28.42
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.
3.76 4.33
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-1.38 9.95
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
3.67 0.65
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-76.75 7.67

Price change ProQR Therapeutics per year

3.60$ 9.09$
Min Max

Summary analysis ProQR Therapeutics

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure ProQR Therapeutics

Revenue and net income ProQR Therapeutics

All parameters

Stock news ProQR Therapeutics

All news
22 December 2022 в 14:30

ProQR Therapeutics Rises on Expanded Lilly Partnership

22 December 2022 в 14:30

ProQR Therapeutics Rises on Expanded Lilly Partnership

13 April 2022 в 15:00

ProQR Therapeutics to Overhaul Development Program, Cut Staff

13 April 2022 в 15:00

ProQR Therapeutics to Overhaul Development Program, Cut Staff

13 April 2022 в 14:55

ProQR Therapeutics to Overhaul Development Program, Cut Staff

13 April 2022 в 14:55

ProQR Therapeutics to Overhaul Development Program, Cut Staff

11 February 2022 в 18:05

ProQR Therapeutics Shares Plumb New Lows After Study Failure >PRQR

11 February 2022 в 18:05

ProQR Therapeutics Shares Plumb New Lows After Study Failure >PRQR

1 February 2022 в 16:00

ProQR Therapeutics started at strong buy with $19 stock price target at Raymond James

9 September 2021 в 17:55

ProQR Therapeutics Shares Rise 29% After Research Deal With Lilly

9 September 2021 в 17:55

ProQR Therapeutics Shares Rise 29% After Research Deal With Lilly

9 October 2019 в 18:11

ЛИДЕРЫ УОЛЛ-СТРИТ-Borr Drillng, Navios Maritime, ProQR Therapeutics

About company ProQR Therapeutics

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase I/II stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase I/II aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as ProQR Therapeutics VIII B.V. for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Address:
Zernikedreef 9, Leiden, Netherlands, 2333 Ck
Company name: ProQR Therapeutics
Issuer ticker: PRQR
ISIN: NL0010872495
Country: Netherlands
Exchange: NASDAQ
Currency: $
IPO date: 2014-09-18
Sector: Healthcare
Industry: Biotechnology
Site: https://www.proqr.com

On which stock exchange are ProQR Therapeutics (PRQR) stocks traded?

ProQR Therapeutics (PRQR) stocks are traded on NASDAQ.

What is the ticker of ProQR Therapeutics stocks (PRQR)?

The stock ticker of ProQR Therapeutics’s stocks or in other words, the code is PRQR. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does ProQR Therapeutics (PRQR) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, ProQR Therapeutics (PRQR) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are ProQR Therapeutics (PRQR) stocks traded?

ProQR Therapeutics (PRQR) stocks are traded on the NASDAQ exchange in dollars.

What is the price of ProQR Therapeutics (PRQR) stocks today?

The current price of ProQR Therapeutics stocks on 16.05.2024 is 1.91 dollars. per share.

What is the dynamics of ProQR Therapeutics (PRQR) stocks from the beginning of the year?

ProQR Therapeutics (PRQR) quotes have increased by -7.95% from the beginning of the year up to 1.91 dollars. per 1 stocks.

How much did ProQR Therapeutics (PRQR) stocks increase in мае 2024?

This month ProQR Therapeutics (PRQR) quotes have increased by -4.5% to 1.91 dollars. per share.

How much are ProQR Therapeutics (PRQR) stocks worth?

Today, on October, 16.05.2024 ProQR Therapeutics’s (PRQR) stocks cost 1.91 dollars..

What is the market capitalization of ProQR Therapeutics (PRQR)?

Capitalization is the market value of ProQR Therapeutics (PRQR) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 16.05.2024, the market capitalization of ProQR Therapeutics (PRQR) is estimated at about 155800663 dollars.